OBJECTIVES: Anti-CD20 (rituximab), anti-CD52 (alemtuzumab), anti-CD22 (BL22, HA22), and anti-CD25 (Oncotac) are therapeutic options that are the mainstay or in preclinical development for the treatment of chronic lymphocytic leukemia (CLL). Studies suggest that levels of surface antigen expression may affect response to monoclonal antibody-based therapy. METHODS: Using the flow cytometric Quantibrite method (BD Biosciences, San Jose, CA) to determine antibodies bound per cell, we quantified the levels of surface expression of CD20, CD22, CD25, and CD52 in CLL cells from 28 untreated patients. RESULTS: The CLL cells in all cases expressed CD20, CD22, and CD52 but 4 (14%) cases were negative for CD25. Although the ranking of levels of expression from highest to lowest was CD52, CD20, CD22, and CD25, the level of antigen expression on any specific case could not be accurately predicted. CONCLUSIONS: Quantification of antigens might be useful in evaluating new antigens to target for therapy and may provide a systematic approach to selecting individualized therapy in CLL.
OBJECTIVES: Anti-CD20 (rituximab), anti-CD52 (alemtuzumab), anti-CD22 (BL22, HA22), and anti-CD25 (Oncotac) are therapeutic options that are the mainstay or in preclinical development for the treatment of chronic lymphocytic leukemia (CLL). Studies suggest that levels of surface antigen expression may affect response to monoclonal antibody-based therapy. METHODS: Using the flow cytometric Quantibrite method (BD Biosciences, San Jose, CA) to determine antibodies bound per cell, we quantified the levels of surface expression of CD20, CD22, CD25, and CD52 in CLL cells from 28 untreated patients. RESULTS: The CLL cells in all cases expressed CD20, CD22, and CD52 but 4 (14%) cases were negative for CD25. Although the ranking of levels of expression from highest to lowest was CD52, CD20, CD22, and CD25, the level of antigen expression on any specific case could not be accurately predicted. CONCLUSIONS: Quantification of antigens might be useful in evaluating new antigens to target for therapy and may provide a systematic approach to selecting individualized therapy in CLL.
Authors: R J Kreitman; I Margulies; M Stetler-Stevenson; Q C Wang; D J FitzGerald; I Pastan Journal: Clin Cancer Res Date: 2000-04 Impact factor: 12.531
Authors: S M O'Brien; H Kantarjian; D A Thomas; F J Giles; E J Freireich; J Cortes; S Lerner; M J Keating Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: William G Wierda; Swaminathan Padmanabhan; Geoffrey W Chan; Ira V Gupta; Steen Lisby; Anders Osterborg Journal: Blood Date: 2011-08-19 Impact factor: 22.113
Authors: William G Wierda; Thomas J Kipps; Jirí Mayer; Stephan Stilgenbauer; Cathy D Williams; Andrzej Hellmann; Tadeusz Robak; Richard R Furman; Peter Hillmen; Marek Trneny; Martin J S Dyer; Swami Padmanabhan; Magdalena Piotrowska; Tomas Kozak; Geoffrey Chan; Randy Davis; Nedjad Losic; Joris Wilms; Charlotte A Russell; Anders Osterborg Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544
Authors: R J Kreitman; W H Wilson; J D White; M Stetler-Stevenson; E S Jaffe; S Giardina; T A Waldmann; I Pastan Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: Clive S Zent; Timothy G Call; Tait D Shanafelt; Renee C Tschumper; Diane F Jelinek; Deborah A Bowen; Charla R Secreto; Betsy R Laplant; Brian F Kabat; Neil E Kay Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: Bérengère Vire; Martin Skarzynski; Joshua D Thomas; Christopher G Nelson; Alexandre David; Georg Aue; Terrence R Burke; Christoph Rader; Adrian Wiestner Journal: Cancer Res Date: 2014-10-24 Impact factor: 12.701
Authors: Meina Liang; Martin Schwickart; Amy K Schneider; Inna Vainshtein; Christopher Del Nagro; Nathan Standifer; Lorin K Roskos Journal: Cytometry B Clin Cytom Date: 2015-07-31 Impact factor: 3.058
Authors: Lili Wang; Rukmini Bhardwaj; Howard Mostowski; Paul N Patrone; Anthony J Kearsley; Jessica Watson; Liang Lim; Jothir Pichaandi; Olga Ornatsky; Daniel Majonis; Steven R Bauer; Heba A Degheidy Journal: PLoS One Date: 2021-03-19 Impact factor: 3.240
Authors: Terry J Fry; Nirali N Shah; Rimas J Orentas; Maryalice Stetler-Stevenson; Constance M Yuan; Sneha Ramakrishna; Pamela Wolters; Staci Martin; Cindy Delbrook; Bonnie Yates; Haneen Shalabi; Thomas J Fountaine; Jack F Shern; Robbie G Majzner; David F Stroncek; Marianna Sabatino; Yang Feng; Dimiter S Dimitrov; Ling Zhang; Sang Nguyen; Haiying Qin; Boro Dropulic; Daniel W Lee; Crystal L Mackall Journal: Nat Med Date: 2017-11-20 Impact factor: 53.440